Compare Novartis AG (NVS) vs Banco Santander SA (SAN) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal from moving averages and a moderate buy consensus from analysts (64% buy ratings). The company reported record profitability in H1 2026 with a net income margin of 26.25% and recently completed the Webster acquisition to expand its U.S. presence, though cash flow trends show recent operational outflows.

SAN's outlook is supported by strong profitability and strategic expansion, but risks include volatile cash flows, high leverage with a debt-to-asset ratio of 17.8, and integration challenges from acquisitions. The stock offers value with a P/E of 14.47, but investors should weigh execution risks against growth potential.